Astec LifeSciences Limited (ASTEC)

Chemicals · Fertilizers & Agrochemicals · NSE · Updated 1 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹655.35 ↓ 25.49% (1Y)

🎯 Key Takeaways

Astec LifeSciences is in a strategic turnaround phase, transitioning from chronic losses to operational stabilization with improving margins and narrowing losses, driven by cost optimization and CDMO expansion. The company has stabilized EBITDA and reduced net losses sequentially, signaling progress in its restructuring and growth initiatives despite revenue volatility.
Revenue declined 4.8% QoQ to ₹94 in Q3FY25.
⚠️ Revenue volatility due to exposure to global agrochemical demand and export markets.

Market Cap

₹1,506

P/E Ratio

-11.3

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About ASTEC 📊 Interactive Charts

📖 The Story

Astec LifeSciences is in a strategic turnaround phase, transitioning from chronic losses to operational stabilization with improving margins and narrowing losses, driven by cost optimization and CDMO expansion. The company has stabilized EBITDA and reduced net losses sequentially, signaling progress in its restructuring and growth initiatives despite revenue volatility.

📰 What's Happening

The company approved unaudited Q1FY27 results showing consolidated revenue of ₹84.3 crore, down 8% YoY, but achieved EBITDA of ₹0.1 crore versus a ₹10.5 crore loss previously, and narrowed net loss to ₹-18.7 crore from ₹-33.0 crore. At the 32nd AGM on July 31, 2026, shareholders approved all resolutions with over 99.9% support, including financial statements and director re-appointment, while ratifying Tapan Gaitonde & Co. as cost auditor for FY2026-27. Management emphasized expanding CDMO capabilities, leveraging R&D infrastructure, and capitalizing on global agrochemical market growth (3.4% CAGR to $301.34B by 2033), with strategic focus on sustainability and global supply chain diversification.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	127	143	111	51	154	69	99	94
Operating Profit	8	5	-2	-17	15	-45	-18	-4
OPM %	4.3%	2.2%	-3.1%	-36.1%	8.3%	-66.7%	-20.0%	-6.1%
Net Profit	-5	-8	-13	-24	-1	-40	-39	-40
EPS	₹-2.54	₹-4.18	₹-6.85	₹-12.41	₹0.50	₹-20.26	₹-19.66	₹-20.59

Revenue has shown mixed trends, declining to ₹84.3 crore in Q1FY27 from ₹91.6 crore in the prior year, but profitability has improved significantly — EBITDA turned positive from a ₹10.5 crore loss, and net loss narrowed to ₹-18.7 crore from ₹-33.0 crore. Earlier quarters revealed volatility, with Q4FY24 showing a rare operational profit of ₹15 crore on ₹154 crore revenue, followed by declines in subsequent quarters. The company has transitioned from deep losses to controlled deficits, with operating margins improving from -66.7% in Q1FY25 to 8.3% in Q4FY24, indicating progress in cost management despite top-line pressure.

🔮 Management Outlook & What's Next

Management did not provide specific financial guidance in the latest filing, but highlighted strategic expansion in CDMO services, sustainability initiatives, and global market opportunities. The focus remains on scaling high-value segments and improving operational resilience, with no disclosed revenue or margin targets beyond broader industry growth trends referenced in the AGM commentary.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Fertilizers & Agrochemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Fertilizers and Chemicals Travancore Limited	57,117	-630.5	—	—	—
Coromandel International Limited	55,044	33.3	—	—	—
UPL Limited	53,373	-157.3	—	—	—
PI Industries Limited	47,259	27.8	—	—	—
Sumitomo Chemical India Limited	22,898	44.4	—	—	—
Bayer Cropscience Limited	21,796	—	—	—	—
Chambal Fertilizers & Chemicals Limited	18,025	11.1	—	—	—
Paradeep Phosphates Limited	12,506	30.3	—	—	—
Sharda Cropchem Limited	8,742	35.8	—	—	—
Rashtriya Chemicals and Fertilizers Limited	6,876	25.9	—	—	—

🔗 Peer Stock Analyses

FACT COROMANDEL UPL PIIND SUMICHEM

⚠️ Risk Factors

1. Revenue volatility due to exposure to global agrochemical demand and export markets. 2. Dependence on raw material supply chains amid geopolitical and trade uncertainties. 3. Execution risks in scaling CDMO capabilities amid competitive and capital-intensive market dynamics. 4. Margin pressure from pricing volatility in a cyclical industry with thin margins.

📋 Recent Filings

🧠 Analyst's Read

Astec LifeSciences is making measurable progress in reducing losses and improving operational efficiency, but revenue contraction and sector-specific headwinds require sustained execution. Investors should monitor margin trends, CDMO segment scalability, and management's ability to convert strategic focus into consistent financial improvement in upcoming quarters.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on ASTEC

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ASTEC files new disclosures

Track ASTEC filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ASTEC — Free

Free account · 2 AI queries/day